Company Overview
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Why Investors Should Care
Maintains a net profit margin of 32.0%.
Recent Developments
- Dec 2025 Revenue of $2.38B (+5.1% YoY); net profit $770.95M.
- Trailing 12 Months Year-on-year growth — revenue +16.5%, earnings -46.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.8%, profit CAGR -9.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.80% |
| 1 Year: | 16.50% |
Compounded Profit Growth
| 5 Years: | -9.22% |
| 1 Year: | -46.30% |
Stock Price Performance
| 1 Year: | +69.75% |
| 6 Months: | +33.30% |
| 3 Months: | +10.89% |
| 1 Month: | +7.16% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)50.15 · Neutral
P/E of 32.58 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 32.0%.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -9.2% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RPRX Royalty Pharma plc R3KPHARMA | 60.59 | 32.58 | $26.98B | 1.60% | 8.21% | 13.96% | 4.80% | -9.22% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 457.61M | 464.28M | 500.88M | 510.93M | 538.40M | 573.03M | 554.96M | 585.77M | 562.05M | 535.96M | 573.46M | 683.97M | 538.20M | 536.31M | 567.98M | 537.27M | 564.69M | 568.25M | 578.66M | 609.29M | 621.99M | 630.58M | 674.14M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.06M | 368.87M | 182.13M | 233.61M | -1.91M | - |
| Operating Income | 327.86M | 532.50M | 361.43M | 409.35M | 510.57M | 229.30M | 744.95M | 303.05M | 219.72M | 377.79M | 192.21M | 478.97M | 248.84M | 151.44M | -73.77M | 269.63M | 735.07M | 534.18M | 209.80M | 427.16M | 388.38M | 632.48M | 133.12M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 499.69M | 160.68M | 525.05M | 451.28M | 563.15M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 65.26M | 68.67M | 79.56M | 94.17M | 93.72M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 434.43M | 90.64M | 444.21M | 355.91M | 468.26M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Net Income | 151.71M | 408.98M | 71.24M | 442.07M | 290.63M | 69.12M | 440.78M | 101.93M | 51.76M | 304.50M | 142.65M | 340.75M | 227.62M | 72.11M | 4.78M | 102.00M | 543.99M | 239.35M | 30.18M | 288.22M | 214.21M | 294.69M | 17.88M |
| Diluted EPS | - | - | - | 0.09 | 0.79 | 0.18 | 1.08 | 0.24 | 0.12 | 0.70 | 0.32 | 0.76 | 0.50 | 0.16 | 0.01 | 0.23 | 1.21 | 0.41 | 0.05 | 0.51 | 0.38 | 0.53 | 0.04 |
| R&D Expense | 21.46M | 22.72M | 7.64M | 5.78M | 5.10M | 2.64M | 3.12M | 90.50M | 100.50M | 606.00K | 25.50M | 500.00K | 500.00K | 50.50M | 500.00K | 500.00K | 500.00K | 50.50M | 300.50M | 50.50M | - | 39.79M | 97.85M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.79B | 1.81B | 2.12B | - | 2.24B | 2.35B | 2.26B | 2.38B |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 1.31B | 862.40M | 971.13M | 818.67M |
| Operating Income | 1.36B | 2.62B | 1.60B | - | 922.89M | 1.49B | 1.29B | 1.56B |
| EBITDA | - | - | - | - | 423.69M | 1.89B | 1.56B | 1.64B |
| Interest Expense | - | - | - | - | 187.96M | 187.19M | 225.51M | 307.66M |
| Pretax Income | - | - | - | - | 230.06M | 1.70B | 1.33B | 1.32B |
| Tax Provision | - | - | - | - | 0 | 0 | 0 | 0 |
| Net Income | 1.38B | 2.35B | 975.04M | - | 42.83M | 1.13B | 858.98M | 770.95M |
| Diluted EPS | - | - | 1.32 | - | 0.10 | 2.53 | 1.45 | 1.37 |
| R&D Expense | 392.61M | 83.04M | 26.29M | 200.08M | 177.11M | 52.00M | 2.00M | 452.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 12.45B | 16.02B | - | 16.81B | 16.38B | 18.22B | 19.62B |
| Current Assets | - | - | - | - | - | 2.55B | 1.27B | 1.80B | 1.53B |
| Cash & Equivalents | - | - | 246.20M | 1.01B | - | 1.71B | 477.01M | 929.03M | 618.70M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 36.60M | 22.41M | 26.96M | 29.32M |
| Total Liabilities | - | - | 6.31B | 6.12B | - | 7.29B | 6.30B | 7.88B | 9.91B |
| Current Liabilities | - | - | 333.42M | 307.89M | - | 1.17B | 161.38M | 1.25B | 636.21M |
| Long Term Debt | - | - | 5.96B | 5.82B | - | 6.12B | 6.14B | 6.61B | 8.57B |
| Total Debt | - | - | - | - | - | 7.12B | 6.14B | 7.61B | 8.95B |
| Total Equity | 4.46B | 4.55B | 6.14B | 9.90B | - | 5.63B | 6.53B | 6.95B | 6.48B |
| Shares Outstanding | - | - | - | - | - | 443.17M | 446.69M | 445.99M | 428.67M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.62B | 1.67B | 2.03B | - | 2.14B | 2.99B | 2.77B | 2.49B |
| Investing Cash Flow | 303.42M | -2.15B | -2.76B | - | -1.03B | -2.07B | -2.68B | -1.61B |
| Financing Cash Flow | -1.38B | -1.19B | 1.49B | - | -944.86M | -2.15B | 361.14M | -1.19B |
| Capital Expenditure | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | 2.14B | 2.99B | 2.77B | 2.49B |
| Net Change in Cash | - | - | - | - | 169.70M | -1.23B | 452.02M | -310.33M |
| Share Buybacks | 0 | 4.27M | 0 | 0 | 0 | 304.76M | 229.65M | 1.23B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | 76.0% | 144.6% | 75.2% | - | 41.3% | 63.4% | 57.1% | 65.6% |
| Net Margin % | 76.8% | 129.4% | 45.9% | - | 1.9% | 48.2% | 37.9% | 32.4% |
| ROE % | 30.3% | 38.2% | 9.9% | - | 0.8% | 17.4% | 12.4% | 11.9% |
| ROCE % | - | 21.6% | 10.2% | - | 5.9% | 9.2% | 7.6% | 8.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Morgan Stanley | 9.64% | 42.93M | $2.51B |
| 2 | Capital International Investors | 7.92% | 35.27M | $2.06B |
| 3 | Blackrock Inc. | 6.25% | 27.83M | $1.63B |
| 4 | FMR, LLC | 5.51% | 24.51M | $1.43B |
| 5 | State Street Corporation | 2.77% | 12.34M | $720.68M |
| 6 | Price (T.Rowe) Associates Inc | 2.51% | 11.19M | $653.82M |
| 7 | Swedbank AB | 2.41% | 10.73M | $626.54M |
| 8 | BAILLIE GIFFORD & CO | 2.25% | 10.02M | $585.01M |
| 9 | Capital World Investors | 2.14% | 9.52M | $555.91M |
| 10 | Geode Capital Management, LLC | 1.81% | 8.06M | $470.67M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RPRX
TD Cowen Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQdmdyU2ZBeTlibUVsRnFoTTVXemRiXzZSM1pBa0Q2SEVsYnFGTDFqdDl4aXlNOEltenFSQm83YVRmTU40MDh0OEw2VnNzbFpHa3A2UFJiWjNGN0YxZENYN2tZQ1JEWnd4QWNMZFhPWXBwOVgyeU53VUZTdzZzMWk5Z3ZvRzB3Mk0yVnAyYj…
How Investors May Respond To Royalty Pharma (RPRX) Pelacarsen Trial Failure - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxOT2pvVXJQRGFJc2NGdzJhZGY0ckduRmVHM3kxM011MjNTYXpUSEhIZTNKOF81ekdZREl1dFkzVU8zYWV4Vzdtb0tPMXFHbEZHcm9rcV83clRjRXZ1QmpUMWF3SmY2YUx1WloyWHdJNmtWQkpCWlNqZjUzMXgzUElxMWV0WkZmSGJiZmZPeG…
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today - Benzinga
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPY0I5MU9YZnhLeFoybE9kbVpIWDh2MGFuS1VUX1RIaFp0MnQ5NUdzaVdKVzFjOUl5WkRpWXNnR3hhakY0dHVZNldSd016cG0zRHhGa29ZSEZ6YVcxcVNLVGgwaC1SWEVwTjM2d3lxS2l1Z18wS1NOSVZWZTNZYWsyeFhFMDNZSGUyWnRaV1…
Royalty Pharma plc (RPRX) Stock Analysis: Navigating Growth with a 16.5% Revenue Surge - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQdG9GT3NRWTF5eHduMmwxRnU1c2hKUTFVRk5BN1NUaUhNelV3MUE0R3djb3Y4RzJEWk92MUpBT2VUcXhJN2ZYZVUxNGwxbG9XWEptYmx3aVVSTTNGUlp0U3pCeXNWd1IyaU1QRFI1S1NsUEJGbFYyQldGaXhDelJfZlhCVTh2SnQxOE5kU0…
Royalty Pharma Slides as Higher-Rate Jitters Seem to Outweigh Recent Strong Results - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQT0RUX3FMd0hLVGFRVlpfZVoxLUVOcVQ1Q0IwYVZjSjJmTFN6YUZmbDRVVlNFZlRZbXAwcWIyc1NGMWVsX2FlNmZoMk5mdFp3MjU5aHAzcjhvSEVMeTg2Q3Z1NG1WZGwwZHJaN3RaTlo4RnVrbzE1NFpYQlZYd01DdDFGWk8zdUJDNnNaSk…
Royalty Pharma (NASDAQ:RPRX) Shares Gap Down - What's Next? - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNbllZZ0VuY3hqcWV6Yi05aDdFczhrN1hpcEVPRExmVEFDWjhfcFJrc2s4ck1Lc3lPOTVlMGJuNHl0WTVrMG1fZ0N2a3JUQXJKUVI2Tmx2dWZSVlJ4d0wzVlFFRnVaSnpxSnNZU19GZFBEYUJzaFdOVDNkcFZhNXktaGFiU2lNZmVLOGNoaW…
RPRX — Frequently Asked Questions
What is the current share price of Royalty Pharma plc (RPRX)?
As of 2026-09-19 21:16 PDT, Royalty Pharma plc (RPRX) trades at $60.59 on NasdaqGS. Its 52-week range is $34.24 to $63.96.
What is the market capitalisation of RPRX?
Royalty Pharma plc (RPRX) has a market capitalisation of $26.98B on NasdaqGS.
What is the P/E ratio of RPRX?
RPRX trades at a trailing price-to-earnings (P/E) ratio of 32.58. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.76.
Does RPRX pay a dividend?
Royalty Pharma plc (RPRX) currently offers a dividend yield of 1.60%.
What is the return on equity (ROE) of RPRX?
RPRX has a return on equity (ROE) of 13.96%. Its return on capital employed (ROCE) is 8.21%.
Is RPRX a good stock to buy?
This page provides a data-driven analysis of Royalty Pharma plc (RPRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.